GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma
Sonia Brun(Genoscience Pharma (France)), Philipe Halfon(Genoscience Pharma (France)), Éric Raymond(Hôpital Paris Saint-Joseph), Philippe Fabre(Sanofi (France)), Christelle Ansaldi(Genoscience Pharma (France)), Firas Bassissi(Genoscience Pharma (France)), Jérôme Courcambeck(Genoscience Pharma (France)), Marie Novello(Genoscience Pharma (France)), Cindy Serdjebi(Genoscience Pharma (France)), Jennifer Tracz(Genoscience Pharma (France)), Marie Guillemot(Evotec (United States)), François Autelitano(Evotec (Germany))
Cited by 39
Related Papers
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
|Annals of Oncology|2015|698
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
|Journal of Clinical Oncology|2008|226
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma <i>via</i> modulation of lysosomal functions
|Autophagy|2021|84
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
|Neuroendocrinology|2018|55